Free Trial
NASDAQ:NXTC

NextCure Q3 2025 Earnings Results & Report

NextCure logo
$6.40 +0.17 (+2.73%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$6.48 +0.07 (+1.17%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextCure beat analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$3.22 versus the -$4.06 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

NextCure EPS Results

Actual EPS
-$3.22
Consensus EPS
-$4.06
Beat/Miss
Beat by +$0.84
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

NextCure Q3 2025 Earnings FAQ

NextCure (NASDAQ:NXTC) reported earnings of -$3.22 per share for Q3 2025, beating the consensus estimate of -$4.06. The report was announced on Wednesday, November 5, 2025.

NextCure Earnings Headlines

NextCure (NASDAQ:NXTC) Rating Lowered to Sell at Wall Street Zen
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
NextCure CMO Departs Amid Pending Avere Merger
NextCure Faces Court Review of Reverse Stock Split
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company researches immunomedicines designed to influence how immune cells recognize and respond to tumors; it does not market approved commercial products.

Its discovery work has included antibody-based and small-molecule candidates aimed at immune-related targets such as Siglec-15, LAIR-1 and CBL-B. NextCure has used its FIND-IT platform to identify and investigate potential therapeutic targets and drug candidates.

Founded in 2015, NextCure is based in Beltsville, Maryland. Its work is centered on oncology research and clinical development.

View NextCure Profile